top of page
Untitled design.png
spravato spray

Welcome to Our Spravato® Treatment Program

At Renew Mental Health & Wellness, we are committed to offering innovative, evidence-based care for individuals struggling with treatment-resistant depression. As part of that commitment, we are proud to provide Spravato® (esketamine)—an FDA-approved therapy designed to help adults who have not found relief with traditional antidepressants.

​

Your Mental Health is Our Priority!

Indications & Limitations of Use.

INDICATIONS:

SPRAVATO® (esketamine) CIII Nasal Spray is indicated for the treatment of:

• Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant.

• Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.

​

LIMITATIONS:

• The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®.

• SPRAVATO® is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO® as an anesthetic agent have not been established.

​

​

IMPORTANT SAFETY INFORAMTION

​

WARNING: SEDATION; DISSOCIATION; RESPIRATORY DEPRESSION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS

See full prescribing information for complete boxed warning

• Risk for sedation, dissociation, and respiratory depression after administration. Monitor patients for at least two hours after administration (5.1, 5.2, 5.3).

• Potential for abuse and misuse. Consider the risks and benefits of using SPRAVATO® prior to use in patients at higher risk of abuse. Monitor for signs and symptoms of abuse and misuse (5.4).

• SPRAVATO® is only available through a restricted program called the SPRAVATO® REMS (5.5).

• Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. SPRAVATO® is not approved for use in pediatric patients (5.6).

ASK
THE EXPERTS

WHAT TO EXPECT
DURING YOUR 
SPRAVATO 
TREATMENT

SPRAVATO INFORMATION

1

ABOUT SPRAVATO

 SPRAVATO®, the only FDA approved nasal spray for adults with treatment-resistant depression, reduces depression symptoms when two or more oral antidepressants haven’t worked. SPRAVATO® can be taken with or without an oral antidepressant.

2

DOSING & ADMINISTRATION

1. Induction Phase (Weeks 1–4):

  • Twice weekly

  • Dose:

    • 56 mg for the first dose

    • Then 56 mg or 84 mg based on tolerability

2. Maintenance Phase:

  • Weeks 5–8: Once weekly (56 mg or 84 mg)

  • Week 9 and beyond: Every 2 weeks or weekly (based on response)

​

3

AFFORDABILITY

Spravato isn’t covered by all insurance plans, and coverage varies. It often requires prior authorization and proof of other failed treatments. Patients should check with their insurer and treatment center to confirm costs and coverage.

bottom of page